T. Rowe Price Associates’s Eton Pharmaceutcials ETON Stock Holding History

T. Rowe Price Associates’s Portfolio ETON Stock Details ETON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$794K	Buy	21,932 +4,280	+24%	+$126K	﹤0.01%	2425
2026 Q1	$436K	Buy	17,652 +2,283	+15%	+$39.9K	﹤0.01%	2518
2025 Q4	$260K	Buy	15,369 +1,845	+14%	+$32.5K	﹤0.01%	2714
2025 Q3	$294K	Buy	13,524 +684	+5%	+$11.4K	﹤0.01%	2612
2025 Q2	$183K	Buy	+12,840	New	+$203K	﹤0.01%	2744
2021 Q4	–	Sell	-24,206	Closed	-$122K	–	3002
2021 Q3	$122K	Sell	24,206 -193,576	-89%	-$1.01M	﹤0.01%	2810
2021 Q2	$1.34M	Buy	+217,782	New	+$1.61M	﹤0.01%	1928

Other funds holding ETON

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

NPT

National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return

T. Rowe Price Associates's ETON Position: Q2 2026 in Review

T. Rowe Price Associates increased its Eton Pharmaceutcials (ETON) stake by 24% in Q2 2026, buying an estimated $126K and bringing the position to 21,932 shares worth $794K. The position accounts for ﹤0.01% of the portfolio, ranked #2425.

T. Rowe Price Associates first reported a position in ETON in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.34M in Q2 2021. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

T. Rowe Price Associates held 21,932 shares of Eton Pharmaceutcials worth $794K as of Q2 2026.
T. Rowe Price Associates bought 4,280 Eton Pharmaceutcials shares in Q2 2026, an estimated $126K.
Eton Pharmaceutcials made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2425 holding.
T. Rowe Price Associates first reported a position in Eton Pharmaceutcials in Q2 2021 and has held it in 7 quarters since.
T. Rowe Price Associates's Eton Pharmaceutcials position peaked at $1.34M in Q2 2021.
164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.